Controlled delivery system
View Patent ↗The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided.
1. A method for providing sustained local anesthesia by administering to a subject a composition comprising:
about 66% by weight sucrose acetate isobutyrate (SAIB) liquid carrier material relative to the total weight of the composition;
about 12% by weight bupivacaine relative to the total weight of the composition; and
about 22% by weight benzyl alcohol (BA) relative to the total weight of the composition,
wherein after administration the bupivacaine is released from said composition for a period of at least 24 hours in an amount sufficient to provide sustained local anesthesia.
2. The method of claim 1 , wherein said composition is administered to a surgical wound.
3. The method of claim 2 , wherein said composition is administered into and/or adjacent to the surgical wound.
4. The method of claim 2 , wherein said composition is administered by pouring.
5. The method of claim 1 , wherein said subject is a human patient undergoing surgical inguinal hernia repair or an appendectomy.
6. The method of claim 1 , wherein said composition is used to treat post-operative pain.
7. The method of claim 1 , wherein the bupivacaine is present in the composition in free base form.
8. The method of claim 1 , wherein administration of said composition provides sustained local anesthesia for a period of at least about 48 hours.
9. The method of claim 1 , wherein administration of said composition provides sustained local anesthesia for a period of at least about 72 hours.